These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38636315)

  • 1. The dynamics of more-than-human care in depot buprenorphine treatment: A new materialist analysis of Australian patients' experiences.
    Barnett A; Pienaar K; Lubman DI; Arunogiri S; Phan V; Hayes V; Lintzeris N; Savic M
    Int J Drug Policy; 2024 May; 127():104399. PubMed ID: 38636315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tracing the affordances of long-acting injectable depot buprenorphine: A qualitative study of patients' experiences in Australia.
    Barnett A; Savic M; Lintzeris N; Bathish R; Arunogiri S; Dunlop AJ; Haber P; Graham R; Hayes V; Lubman DI
    Drug Alcohol Depend; 2021 Oct; 227():108959. PubMed ID: 34450472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Depot buprenorphine injections for opioid use disorder: Patient information needs and preferences.
    Neale J; Tompkins CNE; Strang J
    Drug Alcohol Rev; 2019 Jul; 38(5):510-518. PubMed ID: 31131514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opioid users' willingness to receive prolonged-release buprenorphine depot injections for opioid use disorder.
    Tompkins CNE; Neale J; Strang J
    J Subst Abuse Treat; 2019 Sep; 104():64-71. PubMed ID: 31370986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial.
    Lintzeris N; Dunlop AJ; Haber PS; Lubman DI; Graham R; Hutchinson S; Arunogiri S; Hayes V; Hjelmström P; Svedberg A; Peterson S; Tiberg F
    JAMA Netw Open; 2021 May; 4(5):e219041. PubMed ID: 33970256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring patient experience and satisfaction with depot buprenorphine formulations: A mixed-methods study.
    Allen E; Samadian S; Altobelli G; Johnson J; Holmwood C
    Drug Alcohol Rev; 2023 May; 42(4):791-802. PubMed ID: 36788357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 'Matters-of-concern' associated with discontinuation of long-acting injectable buprenorphine: Findings from a longitudinal qualitative study.
    Parkin S; Neale J; Strang J
    Int J Drug Policy; 2024 Jul; 129():104470. PubMed ID: 38843737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tinkering with care: Implementing extended-release buprenorphine depot treatment for opioid dependence.
    Lancaster K; Gendera S; Treloar C; Rhodes T; Shahbazi J; Byrne M; Nielsen S; Degenhardt L; Farrell M
    Int J Drug Policy; 2024 Apr; 126():104359. PubMed ID: 38382354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged-release opioid agonist therapy: qualitative study exploring patients' views of 1-week, 1-month, and 6-month buprenorphine formulations.
    Neale J; Tompkins CNE; Strang J
    Harm Reduct J; 2019 Apr; 16(1):25. PubMed ID: 30943990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of opioid dependence with depot buprenorphine (CAM2038) in custodial settings.
    Dunlop AJ; White B; Roberts J; Cretikos M; Attalla D; Ling R; Searles A; Mackson J; Doyle MF; McEntyre E; Attia J; Oldmeadow C; Howard MV; Murrell T; Haber PS; Lintzeris N
    Addiction; 2022 Feb; 117(2):382-391. PubMed ID: 34184798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-acting injectable depot buprenorphine from a harm reduction perspective in patients with ongoing substance use and multiple psychiatric comorbidities: a qualitative interview study.
    Johnson B; Monwell B; Capusan AJ
    Harm Reduct J; 2024 Mar; 21(1):68. PubMed ID: 38528531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Long-Acting Buprenorphine Medications for Opioid Dependence: Current Update.
    Soyka M
    Pharmacopsychiatry; 2021 Jan; 54(1):18-22. PubMed ID: 33212514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of an injection depot formulation of buprenorphine: placebo comparison.
    Sigmon SC; Wong CJ; Chausmer AL; Liebson IA; Bigelow GE
    Addiction; 2004 Nov; 99(11):1439-49. PubMed ID: 15500597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transition from methadone to subcutaneous buprenorphine depot in patients with opioid use disorder in custodial setting - a case series.
    Soyka M; Groß G
    Am J Drug Alcohol Abuse; 2021 Sep; 47(5):599-604. PubMed ID: 34407703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Depot buprenorphine as an opioid agonist therapy in New South Wales correctional centres: a costing model.
    Ling R; White B; Roberts J; Cretikos M; Howard MV; Haber PS; Lintzeris N; Reeves P; Dunlop AJ; Searles A
    BMC Health Serv Res; 2022 Nov; 22(1):1326. PubMed ID: 36348369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
    Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
    Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness of Injectable Extended-Release Naltrexone Compared With Methadone Maintenance and Buprenorphine Maintenance Treatment for Opioid Dependence.
    Jackson H; Mandell K; Johnson K; Chatterjee D; Vanness DJ
    Subst Abus; 2015; 36(2):226-31. PubMed ID: 25775099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Open-label, multicentre, single-arm trial of monthly injections of depot buprenorphine in people with opioid dependence: protocol for the CoLAB study.
    Larance B; Byrne M; Lintzeris N; Nielsen S; Grebely J; Degenhardt L; Shahbazi J; Shanahan M; Lancaster K; Dore G; Ali R; Farrell M;
    BMJ Open; 2020 Jul; 10(7):e034389. PubMed ID: 32737087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia.
    Larance B; Degenhardt L; Grebely J; Nielsen S; Bruno R; Dietze P; Lancaster K; Larney S; Santo T; Shanahan M; Memedovic S; Ali R; Farrell M
    Addiction; 2020 Jul; 115(7):1295-1305. PubMed ID: 31860767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Depot buprenorphine during COVID-19 in Australia: Opportunities and challenges.
    Arunogiri S; Lintzeris N
    J Subst Abuse Treat; 2021 May; 124():108221. PubMed ID: 33303254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.